Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¿ø¹ß¼º ¾È¿Í ¸²ÇÁÁ¾ÀÇ ¹æ»ç¼±Ä¡·á ¼ºÀû¿¡ °üÇÑ ÈÄÇâÀû ºÐ¼® Primary Orbital Lymphoma : A Retrospective Analysis of Results of Radiation Therapy

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2002³â 20±Ç 2È£ p.139 ~ 146
¼Ò¼Ó »ó¼¼Á¤º¸
±è¼ö»ê/Su Ssan Kim ¾È½Âµµ/ÀåÇý¼÷/±è°æÁÖ/ÀÌ»ó¿í/ÃÖÀº°æ/±èÁ¾ÈÆ/ÇãÁÖ·É/¼­Ã¶¿ø/±è¼º¹è/Seung Do Ahn/Hye Sook Chang/Kyoung Ju Kim/Sang Wook Lee/Eun Kyung Choi/Jong Hoon Kim/Joo Ryung Huh/Cheol Won Suh/Sung Bae Kim

Abstract

¸ñÀû: ¿ø¹ß¼º ¾È¿Í ¸²ÇÁÁ¾À¸·Î Áø´Ü ¹Þ°í ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº ȯÀÚµéÀ» ´ë»óÀ¸·Î Ä¡·á ¹ÝÀÀ, Àç¹ß ¾ç»ó, »ýÁ¸·ü ¹× Ä¡·á ºÎÀÛ¿ë¿¡ ´ëÇØ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 1991³â 2¿ùºÎÅÍ 2001³â 4¿ù±îÁö ¼­¿ïÁß¾Óº´¿ø¿¡¼­ ¿ø¹ß¼º ¾È¿Í ¸²ÇÁÁ¾À¸·Î Áø´Ü ¹Þ°í ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº 31¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÈÄÇâÀû ºÐ¼®À» ½ÃÇàÇÏ¿´´Ù. ¼ºº°ºÐÆ÷´Â ³²ÀÚ°¡ 18¸í, ¿©ÀÚ°¡ 13¸íÀ̾ú´Ù. ¿¬·ÉÀº 3¼¼¿¡¼­ 73¼¼±îÁö
ºÐÆ÷ÇÏ¿´À¸¸ç
Áß¾Ó°ªÀº 44¼¼¿´´Ù. ¿ø¹ß ºÎÀ§´Â °á¸·ÀÌ 9¸í, ¾È°ËÀÌ 12¸í, ¾È¿Í°¡ 10¸íÀ̾ú´Ù. º´¸®ÇÐÀû ¼Ò°ßÀº MALT (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) ¸²ÇÁÁ¾ÀÌ 28¸í, diffuse large B-cell ¸²ÇÁÁ¾ÀÌ 1¸í, anaplastic large cell ¸²ÇÁÁ¾ÀÌ
1¸íÀ̾úÀ¸¸ç lymphoblastic ¸²ÇÁÁ¾ÀÌ 1¸íÀ̾ú´Ù. Ann Arbor staging¿¡ µû¸¥ º´±â ºÐÆ÷¸¦ »ìÆ캸¸é 1±â°¡ 31¸íÀ¸·Î ÀüºÎ¸¦ Â÷ÁöÇÏ¿´À¸¸ç °¢°¢ ºñÀå, ½ÅÀå, °ñ¼ö¿Í ¸Æ¶ô¾ó±â(choroid plexus)¿¡ º´º¯ÀÌ ÀÖ¾ú´ø ȯÀÚ 4¸íÀº ¿¬±¸¿¡¼­ Á¦¿ÜÇÏ¿´´Ù. Àüü ȯÀÚ Áß, ¾çÃø
¾È¿Í
ħ¹üÀÌ Àִ ȯÀÚ´Â 6¸íÀ̾ú´Ù. ¹æ»ç¼±Ä¡·á´Â °á¸·°ú ¾È°Ë ºÎÀ§´Â 6¡­16 MeVÀÇ ÀüÀÚ¼±À» ÀÌ¿ëÇÏ¿© Àü¹æ 1¹® Ä¡·á·Î 30 §í/10 fractionsÀ» Á¶»çÇÏ¿´°í, ¾È¿Í ºÎÀ§´Â 4 §È, 6 §ÈÀÇ ±¤ÀÚ¼±À» ÀÌ¿ëÇÏ¿© ½û±â¸¦ ÀÌ¿ëÇÑ Àü»ç¹æ 2¹® Ä¡·á·Î 20¡­28ȸ¿¡ °ÉÃÄ ÃÑ 40¡­50.4
§í¸¦
Á¶»çÇÏ¿´´Ù. ƯÈ÷ °á¸·°ú ¾È°Ë ºÎÀ§´Â ¼öÁ¤Ã¼¸¦ º¸È£Çϱâ À§ÇÑ ³³Â÷Æó¹°ÀÌ »ç¿ëµÇ¾ú´Ù. Ç×¾ÏÈ­Çпä¹ýÀº 12¸íÀÇ È¯ÀÚ¿¡¼­ ½ÃÇàµÇ¾ú´Ù. Áß¾Ó ÃßÀû °üÂû±â°£Àº 53°³¿ùÀ̾ú´Ù.

°á°ú: Àüü ȯÀÚÀÇ 5³â »ýÁ¸À²Àº 90.7%À̾úÀ¸¸ç, 2¸íÀÌ Áúº´°ú ¹«°üÇÏ°Ô Æó·Å°ú ºñ¼Ò¼¼Æ÷¼º Æó¾ÏÀ¸·Î »ç¸ÁÇÏ¿© Áúº´°ü·Ã(cause-specific) 5³â »ýÁ¸À²Àº 96.0%À̾úÀ¸¸ç 5³â ¹«º´ »ýÁ¸À²Àº 80.0%, 5³â ±¹¼ÒÁ¦¾îÀ²Àº 90.5%¿´´Ù. ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº 31¸í ¸ðµÎ°¡
Ä¡·á ÈÄ
6°³¿ù À̳»¿¡ ¿ÏÀü°üÇظ¦ º¸¿© ¿ÏÀü°üÇØÀ²Àº 100%¿´´Ù. ÀÌ Áß ±¹¼Ò Àç¹ßÀº ¹æ»ç¼±Ä¡·á ÈÄ 16°³¿ù°ú 18°³¿ù¿¡ 2¸íÀÇ È¯ÀÚ¿¡¼­ º¸¿´°í ±¸Á¦ ¹æ»ç¼±Ä¡·á ÈÄ ¸ðµÎ ¿ÏÀü°üÇظ¦ º¸¿´´Ù. 2¸íÀÌ Á¶»ç¿µ¿ª ¹Û¿¡¼­ Àç¹ßÇÏ¿´°í lymphoblastic ¸²ÇÁÁ¾ ȯÀÚ°¡ ¹æ»ç¼±Ä¡·á ÈÄ
18°³¿ù¿¡
°ñ¼ö¿¡¼­ Àç¹ßÇÏ¿© »ç¸ÁÇÏ¿´°í MALT ¸²ÇÁÁ¾ ȯÀÚ°¡ ¹æ»ç¼±Ä¡·á ÈÄ 41°³¿ù¿¡ Æó¿¡ Àç¹ßÇÏ¿© ±¸Á¦ ¹æ»ç¼±Ä¡·á ÈÄ ¿ÏÀü°üÇظ¦ º¸¿´´Ù. 12¸íÀÇ È¯ÀÚ°¡ ¹æ»ç¼±Ä¡·á Àü¿¡ Ç×¾ÏÈ­Çпä¹ýÀ» ¹Þ¾ÒÀ¸¸ç ºÎºÐ°üÇØ°¡ 11¸í¿¡¼­ ³ªÅ¸³µ°í 1¸íÀº ¹ÝÀÀÀ» º¸ÀÌÁö ¾Ê¾Ò´Ù. ¹æ»ç¼±Ä¡·á
´ç½Ã
½Ã·ÂÀÌ ÀÖ¾ú´ø 29¸í Áß 5¸í¿¡¼­ ¹æ»ç¼±À¯¹ß ¹é³»ÀåÀÌ ¹ß»ýÇÏ¿´À¸¸ç 2¸í¿¡¼­ ¾È±¸°ÇÁ¶ÁõÀÌ ¹ß»ýÇÏ¿´´Ù.

°á·Ð: ¿ø¹ß¼º ¾È¿Í ¸²ÇÁÁ¾ÀÇ ´ëºÎºÐÀÌ MALT ¸²ÇÁÁ¾À̾ú´Ù. ¹æ»ç¼±Ä¡·á´Â ¸Å¿ì ÁÁÀº Ä¡·á ¹ÝÀÀ°ú ±¹¼Ò Á¦¾îÀ²À» º¸¿´À¸¸ç ³ôÀº »ýÁ¸À²À» º¸¿´´Ù. ±¹¼Ò Àç¹ßÇÑ °æ¿ì¿¡µµ ¹æ»ç¼±Ä¡·á°¡ ±¸Á¦Ä¡·áÀÇ ¿ªÇÒÀ» ÇÒ ¼ö ÀÖÀ½À» ¾Ë ¼ö ÀÖ¾úÀ¸¸ç ´ëºÎºÐÀÇ È¯ÀÚ¿¡¼­ ½É°¢ÇÑ
ÈÄÀ¯ÁõÀ» º¸ÀÌÁö ¾Ê´Â ¾ÈÀüÇÑ Ä¡·á·Î »ý°¢µÈ´Ù.

Purpose: This study evaluated the treatment outcomes, patterns of failure, and treatment related complications of primary lymphoma patients who received definitive radiation therapy.

Materials and Methods: A retrospective analysis was undertaken for 31 patients with primary orbital lymphoma at the Asan Medical Center between February 1991 and April 2001. There were 18 males and 13 females with ages ranging from 3 to 73
years
(median, 44 years). The involved sites were 9 conjunctivae, 12 eyelids and 10 other orbits. The histological types were 28 MALT lymphomas (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type), 1 diffuse large B-cell lymphoma, 1
anaplastic large cell lymphoma and 1 lymphoblastic lymphoma. The Ann Arbor stages were all IE (100%). Ann Arbor stage ¥² or ¥³ patients were excluded from this study. Bilateral orbital involvement occurred in 6 cases. Radiation therapy was given
with
one anterior port of high energy electrons (6¡­16 MeV) for the lesions located at the anterior structures like the conjunctivae or eyelids. Lesions with a posterior extension or other orbital lesions were treated with 4 or 6 MeV photons with
appropriately arranged portals. In particular, lens blocks composed of lead alloy were used in conjunctival or eyelid lesions. Twelve patients received chemotherapy. The median follow-up period was 53 months.

Results: The 5-year overall, cause-specific, and disease-free survival was 91%, 96%, and 80%, respectively. The complete response rate 6 months after radiation therapy was 100%. Local recurrences were observed in 2 patients at 16 and 18
months
after completion of radiation treatment. They were salvaged with additional radiation therapy. Two patients developed distant metastases. A MALT lymphoma patient with a lung relapse was successfully salvaged with radiotherapy, but the other
lymphoblastic lymphoma patient with bone marrow relapse expired. There were no severe complications but 5 patients developed radiation-induced cataracts and 2 patients developed dry eye.

Conclusion: Most primary orbital lymphomas consisted of MALT lymphomas. Radiation therapy was a successful treatment modality for orbital lymphoma without any severe complications. In cases of local relapses, radiation therapy is also a
very
successful salvage treatment modality.

Å°¿öµå

¾È¿Í ¸²ÇÁÁ¾; ¹æ»ç¼±Ä¡·á; REAL classification; Orbital lymphoma; Radiation therapy; REAL classification;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS